Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Amplify ETF Trust - Amplify Seymour Cannabis ETF (CNBS)

NYSEArca - NYSEArca Delayed Price. Currency in USD
Add to watchlist
11.23-0.10 (-0.88%)
At close: 03:59PM EST
11.42 +0.19 (+1.69%)
After hours: 07:54PM EST
Advertisement
Sign in to post a message.
  • Y
    Yahoo Finance Insights
    CNBS is down 5.32% to 13.21
  • Y
    Yahoo Finance Insights
    CNBS reached a 52 Week low at 12.97
  • Y
    Yahoo Finance Insights
    CNBS is down 6.44% to 11.18
  • Y
    Yahoo Finance Insights
    CNBS reached a 52 Week low at 12.17
  • G
    George Zipp
    Why is this Fund holding so much Cash ? Anyone
  • Y
    Yahoo Finance Insights
    CNBS reached a 52 Week low at 11.55
  • Y
    Yahoo Finance Insights
    CNBS reached a 52 Week low at 11.55
  • Y
    Yahoo Finance Insights
    CNBS reached a 52 Week low at 12.62
  • j
    jim
    net expense ratio- .75

    Top 10 Holdings
    CURALEAF HOLDINGS SUB VOT SWAP 8.22%
    GREEN THUMB INDUSTRIES SWAP 8.17%
    TILRAY INC 6.82%
    TRULIEVE CANNABIS SWAP 6.26%
    CRESCO LABS SWAP 5.50%
    WM TECHNOLOGY INC 5.34%
    CANOPY GROWTH CORP 5.07%
    VILLAGE FARMS INTL INC 4.78%
    AFC GAMMA INC 4.74%
    INNOVATIVE INDL PPTYS INC 4.34%
    =59.24%
  • A
    Aubrey
    Where is the bottom for MSO’s, Seymour?
  • Y
    Yahoo Finance Insights
    CNBS is down 5.35% to 15.20
  • Y
    Yahoo Finance Insights
    CNBS is down 5.30% to 14.81
  • Y
    Yahoo Finance Insights
    CNBS reached a 52 Week low at 13.93
  • Y
    Yahoo Finance Insights
    CNBS reached a 52 Week low at 13.60
  • J
    JMarsh
    Seymours $CNBS and Harrison’s $MSOS etfs will continue to push this along with accretive acquisitions… in since the teens and not selling for years… will 10x this puppy
    Bullish
  • Y
    Yahoo Finance Insights
    CNBS reached a 52 Week low at 14.39
  • Y
    Yahoo Finance Insights
    CNBS reached a 52 Week low at 15.77
  • Y
    Yahoo Finance Insights
    CNBS is down 5.29% to 16.12
  • j
    jj
    $TCNNF conversation
    $MSOS, $CNBS, $AYRWF, $CCHWF, $CNTMF, $CRLBF, $CURLF, $GTBIF, $JUSHF, $TCNNF, $TRSSF
    Alan Brochstein’s (New Cannabis Ventures) commentary on Florida MSOs

    Friends,

    Florida was one of the most discussed topics on Q1 conference calls across the sector this past month. Cresco Labs, of course, talked about how it plans to scale in the state following the closing of the acquisition of Bluma Wellness in mid-April. Ayr Wellness, which acquired Liberty Health Sciences earlier this year, announced an important change ahead on its conference call: It is moving its corporate headquarters to Florida later this year. GTI, in response to a question, suggested that some of the recently raised capital will be deployed into the state, and Columbia Care and Curaleaf spoke very optimistically about their operations there.

    The state is well penetrated by MSOs, which of course include the market leader, Trulieve, as well as Parallel, Verano, Cansortium, iAnthus, MedMen, Harvest, and Red White & Bloom. The only non-MSO with more than one dispensary open is VidaCann. In fact, of the 339 open stores, over 93% are owned by an MSO. The MSOs sold over 98% of both the flower and the non-flower products in Florida during the most recent week ending May 27th.

    Florida is rather unique, with complete vertical integration. There is no wholesale market: Every gram sold to a customer must be produced by the company operating the dispensary. This past week, the Supreme Court upheld a lower court ruling that had rejected a challenge to vertical integration, removing the risk of the state being required to permit new entrants. Because of the market structure, the operators enjoy extremely high margins.

    The growth of the program has been extraordinary. In the most recent week, the number of patients surpassed 567K (2.5% of the state population), up 65.6% from a year ago and 152% from two years ago:

    We have discussed the resurgence in growth since COVID-19, driven by a number of factors that include the implementation of telehealth for patients to get their cards as well as the recent introduction of edibles. Another factor has been the population growth in the state over the past year.

    Flower wasn't permitted until two years ago and continues its robust growth. Year-to-date, unit volume of cannabis flower has increased 102%, growing faster than the growth in patients. Medical cannabis product units dispensed has grown 82%. BDSA recently began publishing data on the market, with Q1 sales in Florida totaling $392 million. In March, flower and pre-rolls accounted for 49% of the market. Concentrates were 40%, and the recently introduced edibles represented 8% of the market.

    The effort to legalize for adult-use hit a roadblock in April, with a ballot initiative for 2022 struck down by the state's Supreme Court. The timeline for potential legislative action is unclear, but, even without the prospects for adult-use, the booming medical market, with few barriers to access by patients, bodes well for the MSOs operating in Florida. For many of them, the challenge has been scaling cultivation with high temperatures and humidity levels.

    It's easy to see why the MSOs are so excited about Florida. The number of patients continues to soar, the potential for a change to the vertical integration market structure just disappeared, their operations are scaling, and edibles offer another market opportunity.
    Bullish
Advertisement
Advertisement